Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Operating Expenses (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Operating Expenses for 7 consecutive years, with $29.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses fell 47.32% year-over-year to $29.7 million, compared with a TTM value of $176.5 million through Dec 2025, down 17.67%, and an annual FY2025 reading of $176.5 million, down 17.67% over the prior year.
  • Operating Expenses was $29.7 million for Q4 2025 at Keros Therapeutics, roughly flat from $29.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $59.2 million in Q1 2025 and bottomed at $15.6 million in Q2 2021.
  • Average Operating Expenses over 5 years is $37.6 million, with a median of $35.4 million recorded in 2022.
  • The sharpest move saw Operating Expenses surged 96.46% in 2022, then crashed 49.79% in 2025.
  • Year by year, Operating Expenses stood at $24.9 million in 2021, then grew by 28.53% to $32.0 million in 2022, then surged by 45.8% to $46.6 million in 2023, then grew by 20.81% to $56.3 million in 2024, then crashed by 47.32% to $29.7 million in 2025.
  • Business Quant data shows Operating Expenses for KROS at $29.7 million in Q4 2025, $29.6 million in Q3 2025, and $58.0 million in Q2 2025.